EA201390345A1 - Терапевтическое болеутоляющее средство - Google Patents

Терапевтическое болеутоляющее средство

Info

Publication number
EA201390345A1
EA201390345A1 EA201390345A EA201390345A EA201390345A1 EA 201390345 A1 EA201390345 A1 EA 201390345A1 EA 201390345 A EA201390345 A EA 201390345A EA 201390345 A EA201390345 A EA 201390345A EA 201390345 A1 EA201390345 A1 EA 201390345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
present
therapeutic
hsd1
inhibitor
Prior art date
Application number
EA201390345A
Other languages
English (en)
Other versions
EA022338B1 (ru
Inventor
Тецуо Кисо
Мина Цукамото
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201390345A1 publication Critical patent/EA201390345A1/ru
Publication of EA022338B1 publication Critical patent/EA022338B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Предложен фармацевтический препарат, в частности фармацевтическая композиция, который применим для лечения боли. Авторы настоящего изобретения провели интенсивные исследования с применением животных моделей с целью предоставления терапевтического болеутоляющего агента. В результате этого они обнаружили, что ингибитор 11β-гидроксидегидрогеназы типа 1 (11β-HSD1), в частности производное триазола, имеющее циклическую группу в 3 положении (или 5 положении) кольца триазола, обладает полезным действием при уменьшении интенсивности хронической боли. То есть согласно настоящему изобретению фармацевтическая композиция, содержащая ингибитор 11β-HSD1, в частности производное триазола настоящего изобретения, в качестве активного ингредиента, является применимой для лечения боли (в частности, невропатической боли или фибромиалгии).
EA201390345A 2010-09-07 2011-09-06 Применение производных триазола для лечения боли EA022338B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010200305 2010-09-07
PCT/JP2011/070205 WO2012033070A1 (ja) 2010-09-07 2011-09-06 疼痛治療剤

Publications (2)

Publication Number Publication Date
EA201390345A1 true EA201390345A1 (ru) 2013-07-30
EA022338B1 EA022338B1 (ru) 2015-12-30

Family

ID=45810669

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390345A EA022338B1 (ru) 2010-09-07 2011-09-06 Применение производных триазола для лечения боли

Country Status (22)

Country Link
US (2) US9765040B2 (ru)
EP (1) EP2614824B1 (ru)
JP (1) JP5822079B2 (ru)
KR (1) KR101747486B1 (ru)
CN (2) CN107041885A (ru)
AU (1) AU2011299905B2 (ru)
BR (1) BR112013005532A2 (ru)
CA (1) CA2809778C (ru)
CY (1) CY1116274T1 (ru)
DK (1) DK2614824T3 (ru)
EA (1) EA022338B1 (ru)
ES (1) ES2533310T3 (ru)
HR (1) HRP20150544T1 (ru)
IL (1) IL224920A (ru)
MX (1) MX2013002649A (ru)
PL (1) PL2614824T3 (ru)
PT (1) PT2614824E (ru)
SI (1) SI2614824T1 (ru)
TW (1) TWI486336B (ru)
UA (1) UA112418C2 (ru)
WO (1) WO2012033070A1 (ru)
ZA (1) ZA201301458B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851589C (en) 2011-10-18 2019-02-19 Astellas Pharma Inc. Bicyclic heterocyclic compound
US9994658B2 (en) 2015-10-02 2018-06-12 Exxonmobil Chemical Patents Inc. Polymerization process using bis phenolate compounds supported on organoaluminum treated layered silicate supports
RU2643583C1 (ru) * 2016-10-24 2018-02-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО УГМУ Минздрава России) Способ лечения хронических болевых синдромов, сформировавшихся на основе посттравматического стрессового расстройства, сочетающегося с последствиями боевой черепно-мозговой травмы
WO2018117063A1 (ja) * 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
WO2020106337A1 (en) * 2018-11-20 2020-05-28 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR878201A0 (en) * 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
JP2008502301A (ja) * 2003-10-10 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ ペプチドの抱合
US7683059B2 (en) 2003-10-28 2010-03-23 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) * 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
AU2004305321A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
BRPI0417947A (pt) * 2003-12-22 2007-04-17 Lilly Co Eli composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
JP4882748B2 (ja) 2004-09-16 2012-02-22 アステラス製薬株式会社 トリアゾール誘導体またはその塩
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
MX2007016319A (es) 2005-06-16 2008-03-10 Pfizer Derivados de n-(piridin-2-il)-sulfonamida.
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
US7853951B2 (en) * 2005-07-25 2010-12-14 Intel Corporation Lock sequencing to reorder and grant lock requests from multiple program threads
CA2620179C (en) * 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
WO2007105753A1 (ja) 2006-03-16 2007-09-20 Astellas Pharma Inc. トリアゾール誘導体またはその塩
SI2298747T1 (sl) * 2008-07-03 2017-08-31 Astellas Pharma Inc. Derivat triazola ali njegova sol
FR2948211B1 (fr) * 2009-07-17 2011-08-05 Airbus Operations Sas Methode de routage des liaisons physiques d'une plateforme avionique
WO2011068927A2 (en) 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF

Also Published As

Publication number Publication date
CA2809778C (en) 2017-12-12
IL224920A (en) 2017-05-29
EP2614824A4 (en) 2014-02-12
CY1116274T1 (el) 2017-02-08
CA2809778A1 (en) 2012-03-15
ZA201301458B (en) 2014-06-25
AU2011299905A1 (en) 2013-03-21
ES2533310T3 (es) 2015-04-09
PT2614824E (pt) 2015-05-28
EP2614824A1 (en) 2013-07-17
HRP20150544T1 (hr) 2015-06-19
CN107041885A (zh) 2017-08-15
DK2614824T3 (en) 2015-03-23
JPWO2012033070A1 (ja) 2014-01-20
KR101747486B1 (ko) 2017-06-14
KR20130114125A (ko) 2013-10-16
CN103079564B (zh) 2017-06-23
US20130165491A1 (en) 2013-06-27
US20170327474A1 (en) 2017-11-16
EP2614824B1 (en) 2015-03-11
BR112013005532A2 (pt) 2016-05-03
UA112418C2 (uk) 2016-09-12
JP5822079B2 (ja) 2015-11-24
CN103079564A (zh) 2013-05-01
SI2614824T1 (sl) 2015-05-29
TWI486336B (zh) 2015-06-01
WO2012033070A1 (ja) 2012-03-15
EA022338B1 (ru) 2015-12-30
MX2013002649A (es) 2013-04-05
US9765040B2 (en) 2017-09-19
PL2614824T3 (pl) 2015-08-31
TW201302717A (zh) 2013-01-16
AU2011299905B2 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
PH12016502355A1 (en) Pharmaceutical composition
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
IN2012DN06720A (ru)
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
EA201590697A1 (ru) Производные кетамина
NZ607580A (en) N-heteroaryl compounds
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
IN2015DN01329A (ru)
EA201490417A1 (ru) Новые легкоразрушающиеся ингибиторы pde 4
TW201129361A (en) Methods for treating pain
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
IN2015DN00735A (ru)
RS54022B1 (en) COMPOSITION OF VIRUS INHIBITOR FOR INVIVE THERAPEUTIC USE
UA106471U (uk) Засіб для лікування дерматологічних захворювань

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU